Key result
Jun15702 inhibits resistant EV-D68 with ~7-fold greater potency than pleconaril.
Why the study?
Enterovirus D68 lacks vaccines or antivirals, and while capsid inhibitors like pleconaril exhibit potent antiviral activity, they have a low barrier to resistance.
Does targeted protein degradation of viral capsid protein VP1 using the pleconaril-based PROTAC Jun15702 overcome pleconaril resistance and increase the genetic barrier to resistance in Enterovirus D68-infected cells compared to pleconaril?
Does targeted protein degradation of viral capsid protein VP1 using the pleconaril-based PROTAC Jun15702 overcome pleconaril resistance and increase the genetic barrier to resistance in Enterovirus D68-infected cells compared to pleconaril?
This preclinical study establishes targeted PROTAC degradation of a viral structural capsid protein (VP1) as a viable antiviral strategy that retains activity post-viral entry and overcomes drug resistance in Enterovirus D68.
Answers are grounded in this paper and cite their sources.
Supports VP1 degradation as a resistance-overcoming antiviral strategy in EV-D68 models; leaves open clinical translation.
Enterovirus D68 (EV-D68) is an emerging respiratory pathogen with pandemic potential, yet no vaccines or antivirals are available. Capsid inhibitors, such as pleconaril, that target the hydrophobic canyon on the viral capsid protein VP1, exhibit potent antiviral activity but have a low barrier to resistance. Here, we report a targeted protein degradation strategy to overcome antiviral resistance by selectively degrading the capsid protein VP1. Through a structure-based rational design, we developed a series of pleconaril-based PROTACs that recruit the cereblon (CRBN) E3 ligase to degrade the capsid VP1 protein. We established a single-cycle replication assay integrating immunofluorescence and Western blot to quantify VP1 protein levels when compounds were added postviral entry. Linker and CRBN ligand optimization led to the identification of Jun15702, a first-in-class VP1 degrader that displays potent antiviral activity against multiple wild-type EV-D68 strains and retains submicromolar potency against recombinant pleconaril-resistant variant, rMO-VP1 F159 V. Significantly, Jun15702 displayed a higher genetic barrier to drug resistance than pleconaril. Mechanistic studies demonstrate that Jun15702 not only inhibits viral entry, as does pleconaril, but also induces CRBN-dependent degradation of VP1 when added post viral entry. Collectively, this work demonstrates targeted degradation of a viral structural protein as a viable strategy and introduces a new paradigm for overcoming drug resistance in antiviral discovery against enteroviruses.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Enterovirus D68 (EV-D68) infection. Jun15702 (pleconaril-based CRBN-recruiting VP1 PROTAC degrader) vs. Pleconaril, N-methylated control PROTACs (Jun15551, Jun15953), lenalidomide-5-Br, and DMSO control was evaluated on Antiviral potency (EC50) against recombinant pleconaril-resistant EV-D68 variant rMO-VP1 F159V and intracellular VP1 protein degradation. Jun15702 degraded EV-D68 VP1 protein by nearly 10-fold and inhibited the pleconaril-resistant rMO-VP1 F159V variant with 6-fold greater potency than pleconaril (EC50 1,544 nM vs 10,284 nM).
Synapse has enriched 10 related papers. Consider them for comparative context: